Echo Therapeutics Inc fka ECTE

[SD1527]

Demand: By the Numbers: Currently, continuous blood glucose monitoring systems are largely viewed as “generic”. While demand for said devices remains quite brisk and is expected to grow significantly over the next few decades – especially in medical facility environments – not much has come along recently with regard to product differentiation that has prompted end-users to demand a particular product.

Echo Therapeutics, Inc. holds the potential to change all of this and in turn command a sizable share of the BGM market with its upcoming release of the first ever needle-free “trans-dermal” system. Let's take a look at the current state of the target market for Echo's Symphony device and where it is poised to go over the next 5 to 6 years.